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Abstract
Objective The aim was to carry out a retrospective review of the efficacy and safety of anakinra in
paediatric patients with undifferentiated autoinflammatory disease (uAID).
Methods We carried out a retrospective study of children with uAID at a single quaternary centre.
The clinical efficacy of anakinra was evaluated using physician global assessment (PGA) and serologi-
cal response assessed by levels of serum amyloid A and CRP. Safety was assessed by exploring ad-
verse events, including infection and drug reactions.
Results This study included 22 patients, 64% females and 36% males of median age 7.1 years (range
0.13–14.11 years), with uAID. The median starting dose of anakinra was 2 mg/kg (range 2–6 mg/kg) and
the median duration of treatment 19.6 months (range 0.8–100 months). Before anakinra treatment, the
median PGA, on a three-point Likert scale, was 2 (range 1–2), which fell to 1 (range 0–2) within
3 months of treatment. Eight of 22 (36%) patients achieved complete clinical and serological remission;
8/22 (36%) achieved a partial response; and 6/22 (28%) had no response to anakinra. Adverse events
included death (3/22, 14%) and allogeneic haematopoietic stem cell transplantation (1/22, 5%). There
were no new safety signals, and anakinra was well tolerated overall.
Conclusion Retrospectively, 72% of children with uAID responded well to anakinra, with 36% achiev-
ing full clinical and serological remission within 3 months. This suggests that empirical trials of IL-1
blockade might be warranted in children with uAID. Clear stopping criteria based on predefined param-
eters should be considered, because non-responders required alternative therapies, facilitated by a de-
finitive molecular diagnosis where possible.
Key words: undifferentiated autoinflammatory disease, unclassified autoinflammatory disease, child, anakinra,
IL-1 receptor antagonist
Key messages
. Undifferentiated autoinflammatory diseases carry a significant disease burden, and there is a limited therapeutic
evidence base.
. Anakinra is efficacious in some undifferentiated autoinflammatory diseases despite the absence of a firm
molecular diagnosis.
. Molecular diagnoses for undifferentiated autoinflammatory disease must be continuously re-evaluated as novel
pathogenic variants are regularly described.
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Introduction
Autoinflammatory diseases (AIDs) are characterized by
inflammation caused by abnormal dysregulation of the
innate immune system that leads to periodic fevers, vari-
ous inflammatory cutaneous manifestations, arthritis,
CNS inflammation, inflammatory eye disease, myalgia,
serositis, and, in children, delay of growth and puberty
[1]. Untreated, all AIDs are associated with risk of organ
failure and death from reactive Amyloid A amyloidosis
[2]. Clinical trials have demonstrated that IL-1 blockade
with the IL-1 receptor antagonist anakinra or the mono-
clonal antibody against IL-1b canakinumab are highly ef-
fective for cryopyrin-associated periodic syndromes
(CAPS) and, more recently, have demonstrated efficacy
for TNF receptor-associated periodic fever syndrome
(TRAPS), mevalonate kinase deficiency (MKD) and col-
chicine-resistant FMF (crFMF) [3]. Anakinra has recently
been licensed in Europe for systemic JIA and adult-
onset Still’s disease [4].
These therapeutic advances represent important prog-
ress for AID patients, but an important challenge is how
to treat patients with unclassified or undifferentiated
autoinflammatory disease (uAID), who do not have ge-
netic confirmation of CAPS, TRAPS, MKD or FMF.
Published data regarding the use of anakinra for uAID is
extremely limited, with one retrospective report pertain-
ing to 11 adults with uAID [5] that suggested anakinra
as a viable treatment option. No studies relate to the
use of anakinra for uAID in children. The purpose of this
study was to describe retrospectively the use of ana-
kinra for paediatric uAID patients.
Methods
This was a single-centre retrospective review of paediat-
ric patients referred to the autoinflammation service at
Great Ormond Street Hospital between January 2009
and January 2018. Inclusion criteria were patients with a
diagnosis of uAID, fulfilling a pre-specified definition (see
below - Patients section), who received anakinra. Ethical
approval was received by the Joint Research and
Development department at Great Ormond Street
Hospital (reference number: 17IR33). Given that this was
a retrospective review of anonymized un-identifiable
data, it was exempt from National Health Service (NHS)
Research Ethics Committee approval, and consent was
not required from individual patients.
Patients
For the purpose of this study, the diagnosis of uAID re-
quired the presence of systemic inflammation, with or
without periodic fevers, plus the following key exclu-
sions: a genetic diagnosis of CAPS, FMF, MKD or
TRAPS; periodic fever, aphthous stomatitis, pharyngitis
and adenopathy syndrome, because this syndrome
rarely requires treatment with anakinra [6]; systemic JIA
that fulfilled the International League of Association for
Rheumatology criteria, because anakinra is now licensed
for this indication [4]; and other obvious causes of sys-
temic inflammation, including infection, malignancy or
autoimmunity. Clinical features collected were adapted
from the autoinflammatory disease activity index (AIDAI)
tool [7].
Outcomes
The physician global assessment (PGA) was used as a
primary outcome measure of overall clinical disease ac-
tivity and was extracted retrospectively from clinical
records using a three-point Likert scale: 0¼no to mini-
mal activity; 1¼mild to moderate activity; and
2¼ severe activity. The co-primary outcome measure
was normalization (or reduction) of CRP (normal range
0–20 mg/l) and serum amyloid A (normal range 0–10
mg/l) 3 months after starting anakinra. These outcomes
were divided into three categories as defined below.
Complete response (remission)
Efficacy of anakinra was divided into three sub-
categories of complete response: clinical remission,
PGA¼0/2; serological remission, normal CRP/serum
amyloid A levels; and complete remission, clinical and
serological remission.
Partial response
This was defined clinically as a change from a Likert
category to the category below and/or serologically as a
50% reduction in CRP, but not in the normal range (0–
20 mg/l).
No response
This category included patients who failed to meet the
criteria for remission or partial response (as above) and
patients who died or needed allogeneic haematopoietic
stem cell transplantation despite anakinra.
Secondary outcome measures included analysis of
adverse effects and laboratory parameters: ESR, hae-
moglobin concentration, white blood cell count and
platelet count; and analysis of the daily prednisolone
dose at each of the time points studied.
Stopping criteria and anakinra treatment duration
Reason(s) for stopping anakinra were collated. These in-
cluded lack of improvement of PGA and/or acute-phase
reactants, or the development of adverse events.
Generally, 3 months of anakinra was regarded (in our rou-
tine clinical practice) as the minimal duration to gauge
therapeutic response; patients with partial response con-
tinued treatment for 6 months before terminating it.
Statistical analyses
Non-parametric descriptive statistics were used for nu-
merical data, and expressed as the median and range.
A two-tailed Wilcoxon signed-rank test was used to
compare numerical data before and after anakinra to
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note the presence of a significant difference. Fisher’s
exact test was used to compare the response to
anakinra with baseline CRP or serum amyloid A levels.
A P-value< 0.05 was considered statistically significant
for all tests. All tests were performed using International
Business Machines Statistical Package for Social
Sciences version 25.
Results
Patient characteristics
Between January 2009 and January 2018, 54 children
treated for rheumatological conditions at Great Ormond
Street Hospital received anakinra for miscellaneous di-
agnoses. Of these, 32 were excluded from our study be-
cause they did not meet the inclusion criteria for uAID
as defined above. There were 64% females (14/22) and
36% males (8/22). The median age at symptom onset
was 0.61 years (range 0–13.5 years), with 14/22 children
presenting in the first year of life. Consanguinity was
present in 4/22. A family history of inflammatory rheuma-
tological conditions was present in 7/22.
Baseline clinical features
Clinical features are summarized in Supplementary
Table S1, available at Rheumatology Advances in
Practice online. CSs were used in 11/22 patients at ana-
kinra introduction. NSAIDs were used in 3/22. DMARDs
were prescribed to 13/22 children: MTX (n¼ 5), CSA
(n¼3), AZA (n¼4), and MMF (n¼1). Anakinra was com-
menced because of lack of adequate clinical response
to these previous treatments. The median age at
commencement of anakinra was 7.1 years (range 0.13–
14.11 years). Immediately before starting anakinra, the
median PGA was 2 (range 1–2), CRP was raised in
13/22 patients [median 39 mg/l (range 5–344 mg/l)], and
4/22 patients did not have serum amyloid A recorded,
while 10/18 patients had elevated serum serum amyloid
A levels [median 122 mg/l (range 2–637 mg/l)].
Response to anakinra
Twenty-one of 22 children started anakinra 2 mg/kg/day
injections. Patient 4 started 6 mg/kg injections, owing to an
episode of secondary haemophagocytic lymphohistocyto-
sis at the time of commencement (Table 1). This was ta-
pered to 1 mg/kg/day as the disease went into remission.
Twelve of 22 patients required increased anakinra doses to
control their disease, with a maximal increase of 6 mg/kg
for patient 3. All children received anakinra daily, with the
exception of two patients who were on alternate-day injec-
tions: patient 11 was on peritoneal dialysis, hence the re-
duced dosage; and patient 18 was in remission, which led
to a switch from daily to alternate-day injections.
Physician global assessment
PGA was scored on a three-point Likert scale at differ-
ent intervals after starting anakinra. At the time of
starting anakinra, 77% (17/22) patients had PGA¼2 (se-
vere disease activity), and 23% (5/22) had PGA¼ 1 (mild
to moderate activity). The number of patients with
PGA¼2 decreased over the course of anakinra treat-
ment. Within 3 months, 45% (9/20) of patients had
PGA¼0 (minimal disease activity), and this increased to
55% (10/18) within 6 months (Supplementary Table S2).
The increased number of patients with PGA¼2 (27%, 6/
22 patients) at the last follow-up was because this time
point included patients who discontinued anakinra ow-
ing to intolerance or ineffectiveness and included 3/22
patients who died (14%; patients 5, 6 and 7), 1/22
patients who received allogeneic haematopoietic stem
cell transplantation (5%; patient 9) and another patient
with severe tonsillitis and periorbital cellulitis, which ne-
cessitated stopping anakinra (patient 17; Table 1).
Acute phase reactants and serological markers
Ninety per cent (18/20) of patients achieved a normal
CRP within 3 months, and 94% (17/18) had achieved
this within 6 months of treatment. Seventy per cent (14/
20) of patients achieved a normal serum amyloid A level
within 3 months, while 10% (2/20) had a50% decrease
in serum amyloid A levels from baseline, which had not
normalized. Within 6 months, 72% (13/18) had achieved
normal serum amyloid A levels.
Two patients, patients 9 and 13, ended treatment be-
fore the 3 months mark owing to an incomplete re-
sponse to anakinra. Two more patients (patient 14, with
inadequate symptom control; and patient 20, for whom
anakinra worked but who was switched to canakinu-
mab, patient choice) ended treatment before the
6 months follow-up. Given that these patients stopped
anakinra before the 3 and 6 months follow-ups, they
were excluded from the respective time point analyses,
and it was assumed that patients 9, 13 and 14 had
failed treatment.
Efficacy results at 3 and 6 months after anakinra com-
mencement are summarized in Tables 1 and 2. PGA
and CRP improved at 3 and 6 months, and PGA at the
last visit was also significantly improved while still on
anakinra. A similar trend was observed for serum
amyloid A, ESR and haemoglobin. There were non-
statistically significant changes in white blood cell and
platelet counts. Baseline CRP or serum amyloid A did
not predict response to treatment with anakinra
(Table 1; Fisher’s exact test, P-value ¼ non-significant,
data not shown).
Safety
Three main subtypes of adverse effects recorded in this
study were as follows: injection-site reactions (erythema
and pain around injection site [11]), infections and neu-
tropenia. Fifteen of 22 had a median of one adverse
event (range 0–2): infection (n¼ 8); neutropenia (n¼7);
and injection-site reaction (n¼5). Twelve events in 10/
22 patients were deemed serious and required hospital
admission: three patients had painful injection-site
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reactions requiring presentation to their local hospital,
although none of these ultimately required specific inter-
vention or cessation of treatment. Serious infections re-
quiring hospital intervention were as follows: presumed
viral infection (no further details provided) with disease
flare (n¼ 1); urinary tract infection and concomitant vari-
cella zoster virus infection (n¼ 1); presumed viral upper
respiratory tract infection (n¼ 1); suspected sepsis (no
organism isolated) and disease flare (n¼ 1); and orbital
cellulitis (no organism isolated; n¼ 1; Supplementary
Table S3, available at Rheumatology Advances in
Practice online). Neutropenia requiring presentation to
the patients’ local hospital was detected on blood moni-
toring in three patients, all self-limiting (but no further
details were available). Eight events in 6/22 patients
were deemed not serious and did not require hospitali-
zation (Supplementary Table S3, available at
Rheumatology Advances in Practice online).
Three patients died. One died while on anakinra (pa-
tient 5; Table 1) from macrophage activation syndrome
in the context of the unclassified autoinflammatory dis-
order, and two patients died from multiorgan failure at-
tributable to their underlying disease having stopped
anakinra previously (patients 6 and 7; Table 1).
Duration of treatment and discontinuation
At the last clinical follow-up, 7/22 patients were still on
anakinra treatment, with 6/7 in remission. The median
treatment duration for the other 15 patients was
5.1 months (range 0–100 months). The reasons for dis-
continuation included the following: lack of efficacy (8/
15, 53%); death (3/15, 20%); disease in remission (2/15,
13%); intolerance (1/15, 7%); and change in diagnosis
(1/15, 7%) (Supplementary Figure S1, available at
Rheumatology Advances in Practice online).
TABLE 2 Results of physician global assessment and serological markers at various time points throughout treatment
Baseline
(n5 22)
3 months
(n520)
6 months
(n5 18)
Last visit on anakinra
[median 19 months
(range 1–100months)]
(n5 22)
Last visit off anakinra
[median 35 months
(range 11–153months)]
(n5 15)
Primary outcome measures
Physician global assessment 2 (1–2) 1 (0–2) 0 (0–2) 0 (0–2) 0 (0–2)
CRP (mg/l) 41 (5–344) 5 (1–26) 5 (1–53) 6 (1–350) 5 (1–20)
P¼0.001 P¼0.007 P¼0.08 P¼0.018
Serum amyloid A (mg/l) 146 (3–637) 4 (3–216) 3 (1–32) 5 (3–58) 3.3 (3–4)
P¼0.012 P¼0.075 P¼0.028 P¼0.109
Secondary laboratory outcome measures
ESR (mm/h) 50 (3–100) 10 (1–52) 17 (4––50) 14 (2–110) 7 (2–110)
P¼0.023 P¼0.025 P¼0.086 P¼0.017
Hb (g/l) 110 120 121 122 130
(76–126) (90–145) (107–129) (70–155) (96–135)
P¼0.002 P¼0.021 P¼0.02 P¼0.021
WBC count (109/l) 11 (3–7) 8 (3–14) 7 (3–13) 9 (2–24) 6 (3–24)
P¼0.088 P¼0.173 P¼0.233 P¼0.401
Platelets 393 (107–615) 321 385 298 312
(196–653) (130–530) (204–493) (202–430)
P¼1 P¼0.176 P¼0.363 P¼0.674
Baseline
(n¼11)
3 months
(n¼11)
6 months
(n¼8)
Last visit on anakinra
[median 19 months
(range 1–100)] (n¼8)
Last visit off anakinra
[median 35 months
(range 11–153)]
Daily prednisolone dose analysis
Prednisolone (mg/kg) 0.33 0.32 0.30 0.08 N/A
(0–1.43) (0.06–2) (0–0.71) (0–1.25)
P¼0.241 P¼0.161 P¼0.398
All results are displayed as the median (range). The P-values represent comparison at 3 and 6 months and last clinical fol-
low-up (on and off anakinra) compared with the baseline for each variable using the two-tailed Wilcoxon signed-rank pair
test; P-values < 0.05 were considered significant and are highlighted in bold. The daily prednisolone dose (in milligrams
per kilogram body weight) was analysed at baseline, 3 and 6 months after commencing anakinra and the last visit on ana-
kinra. Physician global assessment ranges from zero to two, where two represents maximal disease activity and zero rep-
resents minimal disease activity. ESR, normal range 0–10 mm/h; N/A: not applicable (the daily prednisolone dose was not
analysed after patients stopped anakinra, because the primary aim of analysing the daily doses was to looking for a ste-
roid-sparing effect of anakinra); serum amyloid A, normal range 0–10 mg/l; WBC count: white blood cell count, normal
range 4  109 to 11  109/l.
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Diagnostic impact of further genetic testing
At the start of the study in 2009, standard fever gene
screening for patients with periodic fevers focused only
on TRAPS, CAPS, MKD and FMF, thus patients with
negative screening for these diseases were designated
as uAID. Over the course of the study, however, the pa-
tient cohort underwent additional genetic testing (Sanger
and/or next generation sequencing), with diagnostic im-
pact on 8/22 (38%) patients. The final diagnoses are
summarized in Table 2.
Discussion
The aim of this study was to explore retrospectively the
safety and efficacy of anakinra in uAID paediatric
patients, because these data are currently lacking.
Retrospectively, we observed that 36% (8/22) of
patients achieved complete remission within 3 months
of starting anakinra and remained in remission at their
last clinical follow-up, indicating that the initial response
to anakinra was a reliable predictor of longer-term effi-
cacy. Thirty-six per cent (8/22) had a partial response.
The remaining 28% (6/22) patients had no discernible
response to anakinra. Baseline CRP or serum
amyloid A did not predict response to anakinra.
Empirical trials of biologics or other immunomodulators
are thus justifiable despite a lack of high-level evidence,
because our observation of significant mortality (14%)
or the need for haematopoietic stem cell transplantation
(5%) demonstrated the severity of uAID in some
patients.
Anakinra might not be effective for all uAID patients; in
this series, 15/22 stopped anakinra for the following rea-
sons: lack of efficacy (53%); death (20%); remission
(13%); intolerance to daily injections (7%); and change of
diagnosis (7%). Further genetic testing of this series of
uAID patients resulted in a definitive molecular diagnosis
in 36% of the patients (patients 1, 6, 7, 8, 10, 16, 17 and
18), comparable to a previous report on the clinical im-
pact of next generation sequencing in such patients [8],
with therapeutic implications in some patients. With re-
gard to safety, unlike previous studies, the most com-
mon side effect was not injection-site reactions [11], but
infection. Previous studies have reported that IL-1 block-
ade leads to increased susceptibility to infections [12].
The frequency of injection-site reaction was perhaps
lower in this cohort owing to concomitant oral and/or
topical CSs, which reduce the severity and incidence of
injection-site reactions [13]. Overall, anakinra was well
tolerated, with no new safety signals.
Our study is limited by all the caveats around a retro-
spective case series and is thus certainly subject to
bias. Simple parameters, such as the PGA, and serolog-
ical responses (CRP and serum amyloid A ) have been
used in other clinical trials of autoinflammation [14, 15]
and have thus faced validation in this context.
Unfortunately, patient-reported quality-of-life data were
not collected in this retrospective study, which is a limi-
tation of our study.
Advances in next generation sequencing technologies
have had significant clinical diagnostic impact for
patients with autoinflammation [8] and in the future will
be key to realizing the vision of precision medicine of
more targeted treatments for uAID patients. In the
meantime, empirical trial of IL-1 blockade with anakinra
is arguably justifiable for paediatric patients with uAID,
because a significant proportion will respond, and this is
a safe approach.
Acknowledgements
P.B. acknowledges support from Great Ormond Street
Hospital Children’s Charity. All research at Great Ormond
Street Hospital NHS Foundation Trust and University
College London Great Ormond Street Institute of Child
Health is made possible by the National Institute for
Health Research (NIHR) Great Ormond Street Hospital
Biomedical Research Centre. The views expressed are
those of the author(s) and not necessarily those of the
NHS, the NIHR or the Department of Health.
Funding: No specific funding was received from any
funding bodies in the public, commercial or not-for-
profit sectors to carry out the work described in this
manuscript.
Disclosure statement: P.B. declares consultancy fees
from Novartis, Swedish Orphan Biovitrum and Roche.
D.E. has received institutional grants and consultancy
fees from Pfizer, Lilly and Roche. The other authors
have declared no conflicts of interest.
References
1 Russo RAG, Brogan PA. Monogenic autoinflammatory
diseases. Rheumatology 2014;53:1927–39.
2 Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr
Opin Pharmacol 2006;6:214–20.
3 European Medicines Agency. EPAR summary for the
public [Internet]. London: European Medicines Agency;
2017 p. 1-3. https://www.ema.europa.eu/documents/
overview/ilaris-epar-summary-public_en.pdf.
4 European Medicines Agency. New treatment option for
rare inflammatory disease [Internet]. 2018. https://www.
ema.europa.eu/en/news/new-treatment-option-rare-
inflammatory-disease.
5 Harrison SR, McGonagle D, Nizam S et al. Anakinra as a
diagnostic challenge and treatment option for systemic
autoinflammatory disorders of undefined etiology. JCI
Insight 2016;1:e86336.
6 Vanoni F, Theodoropoulou K, Hofer M. PFAPA
syndrome: a review on treatment and outcome. Pediatr
Rheumatol Online J 2016;14:38.
7 Piram M, Kone´-Paut I, Lachmann HJ et al. Validation of
the auto-inflammatory diseases activity index (AIDAI) for
Suchika Garg et al.
6 https://academic.oup.com/rheumap
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
ap/article-abstract/3/1/rkz004/5316234 by U
niversity C
ollege London user on 28 August 2019
hereditary recurrent fever syndromes. Ann Rheum Dis
2014;73:2168–73.
8 Omoyinmi E, Standing A, Keylock A et al. Clinical impact
of a targeted next-generation sequencing gene panel for
autoinflammation and vasculitis. PLoS One 2017;12:
e0181874.
9 Brehm A, Liu Y, Sheikh A et al. Additive loss-of-function
proteasome subunit mutations in CANDLE/PRAAS
patients promote type I IFN production. J Clin Invest
2015;125:4196–211.
10 Standing ASI, Malinova D, Hong Y et al.
Autoinflammatory periodic fever, immunodeficiency, and
thrombocytopenia (PFIT) caused by mutation in actin-
regulatory gene WDR1. J Exp Med 2017;214:59–71.
11 European Medicines Agency. Kineret: EPAR - Product
Information [Internet]. European Medicines Agency;
2009. https://www.ema.europa.eu/documents/
product-information/kineret-epar-product-information_
en.pdf.
12 Hoffman HM. Therapy of autoinflammatory syndromes. J
Allergy Clin Immunol 2009;124:1129–38.
13 Kaiser C, Knight A, Nordstro¨m D et al. Injection-site
reactions upon Kineret (anakinra) administration: experiences
and explanations. Rheumatol Int 2012;32:295–9.
14 Quartier P, Allantaz F, Cimaz R et al. A multicentre,
randomised, double-blind, placebo-controlled trial with
the interleukin-1 receptor antagonist anakinra in patients
with systemic-onset juvenile idiopathic arthritis (ANAJIS
trial). Ann Rheum Dis 2011;70:747–54.
15 Russo RAG, Melo-Gomes S, Lachmann HJ et al.
Efficacy and safety of canakinumab therapy in paediatric
patients with cryopyrin-associated periodic syndrome: a
single-centre, real-world experience. Rheumatology
2014;53:665–70.
Anakinra for undiffereniated autoinflammatory disease in children
https://academic.oup.com/rheumap 7
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
ap/article-abstract/3/1/rkz004/5316234 by U
niversity C
ollege London user on 28 August 2019
